Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy
James B. Brock, Peyton Herrington, Melissa Hickman, Aubri B. Hickman
Abstract
We report 12 patients with persistent viremia on oral antiretroviral therapy who were initiated on injectable cabotegravir/rilpivirine (iCAB/RPV) without oral lead-in. All patients achieved viral suppression without any virologic rebound. iCAB/RPV may be considered as an option for patients unable to maintain suppression on oral antiretroviral therapy.
Topics & Concepts
RilpivirineMedicineAntiretroviral therapyViremiaInternal medicineHuman immunodeficiency virus (HIV)Antiretroviral drugViral loadVirologyHIV Research and TreatmentHIV/AIDS drug development and treatmentHepatitis C virus research